miR-122 negatively correlates with liver fibrosis as detected by histology and fibroscan

World Journal of Gastroenterology

Volumn 21, Issue 25, 2015, Pages 7814-7823

  Halász, Tünde ^a,b   Horváth, Gábor ^c   Pár, Gabriella ^d   Werling, Klára ^a   Kiss, András ^a   Schaff, Zsuzsa ^a   Lendvai, Gábor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Military Hospital   (Hungary)

^c Hepatology Center of Buda   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Expression; FibroScan; Liver fibrosis; METAVIR; microRNA; miR 122

Indexed keywords

ALANINE AMINOTRANSFERASE; MICRORNA; MICRORNA 122; MICRORNA 21; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 224; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GENETIC MARKER; MIRN122 MICRORNA, HUMAN;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLIC FATTY LIVER; ARTICLE; AUTOIMMUNE LIVER DISEASE; DISEASE SEVERITY; ELASTOGRAPH; ELASTOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; RNA ISOLATION; SCORING SYSTEM; BIOPSY; BLOOD; CHEMISTRY; DIAGNOSTIC IMAGING; DOWN REGULATION; GENETIC MARKER; GENETICS; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ALANINE TRANSAMINASE; BIOMARKERS; BIOPSY; DOWN-REGULATION; ELASTICITY IMAGING TECHNIQUES; GENETIC MARKERS; HUMANS; LIVER; LIVER CIRRHOSIS; MICRORNAS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84936741686     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i25.7814     Document Type: Article

References (52)

1. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195-206 [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005]
2. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011;193:225-231 [PMID: 21803030 DOI: 10.1016/j.cbi.2011.07.001]
3. Chen SL, Zheng MH, Shi KQ, Yang T, Chen YP. A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job. BioDrugs 2013;27:25-34 [PMID: 23329398 DOI: 10.1007/s40259-012-0005-2]
4. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007;381:107-113 [PMID: 17399697]
5. Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, Brown KE, Burge CB, Schmidt WN, Wang Y, McCaffrey AP Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis 2011;203:1753-1762 [PMID: 21606534 DOI: 10.1093/infdis/jir186]
6. Haybaeck J, Zeller N, Heikenwalder M. The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Med Wkly 2011;141:w13287 [PMID: 22020555 DOI: 10.4414/smw.2011.13287]
7. He Y, Huang C, Zhang SP, Sun X, Long XR, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012;24:2268-2272 [PMID: 22884954 DOI: 10.1016/j.cellsig.2012.07.023]
8. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M. microRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis. Front Physiol 2012;3:49 [PMID: 22457651 DOI: 10.3389/fphys.2012.00049]
9. Fowell AJ, Iredale JP Emerging therapies for liver fibrosis. Dig Dis 2006;24:174-183 [PMID: 16699275]
10. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-1457 [PMID: 14647056]
11. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273-1281 [PMID: 20026422 DOI: 10.1016/j.biocel.2009.12.014]
12. El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, El Akel WA, Esmat G. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int 2013;33:982-990 [PMID: 23509874 DOI: 10.1111/liv. 12139]
13. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350 [PMID: 15685546]
14. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs.liver biopsy? Liver Int 2011;31 Suppl 1:13-17 [PMID: 21205132 DOI: 10.1111/j. 1478-3231.2010.02380.x]
15. Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, Crisan D, Sparchez Z, Iancu S, Maniu A. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010;19:53-60 [PMID: 20361076]
16. Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell 2012;3:364-371 [PMID: 22610888 DOI: 10.1007/s13238-012-2036-3]
17. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10:542-552 [PMID: 23689081 DOI: 10.1038/nrgastro.2013.87]
18. Gyugos M, Lendvai G, Kenessey I, Schlachter K, Halász J, Nagy P, Garami M, Jakab Z, Schaff Z, Kiss A. MicroRNA expression might predict prognosis of epithelial hepatoblastoma. Virchows Arch 2014;464:419-427 [PMID: 24570391 DOI: 10.1007/s00428-014-1549-y]
19. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL, Schrum LW. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012;56:300-310 [PMID: 22278637 DOI: 10.1002/hep. 25613]
20. Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I, Molnar L, Von Brandenstein M, Töx U, Nischt R, Coutelle O, Dienes HP, Odenthal M. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One 2011;6:e24568 [PMID: 21931759 DOI: 10.1371/journal.pone.0024568]
21. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009;583:759-766 [PMID: 19185571 DOI: 10.1016/j.febslet.2009.01.034]
22. Ciesla M, Skrzypek K, Kozakowska M, Loboda A, Jozkowicz A, Dulak J. MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem 2011;401:2051-2061 [PMID: 21544542 DOI: 10.1007/s00216-011-5001-8]
23. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012;56:1371-1383 [PMID: 22314424 DOI: 10.1016/j.jhep. 2011.11.026]
24. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832 [PMID: 9121257]
25. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2008;10:203-211 [PMID: 18403610 DOI: 10.2353/jmoldx.2008.070153]
26. Andersen CL, Jensen JL, Ørntoft TF. Normalization of realtime quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004;64:5245-5250 [PMID: 15289330]
27. Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur J Gastroenterol Hepatol 2010;22:474-480 [PMID: 19887952 DOI: 10.1097/MEG.0b013e328332dd0a]
28. Gómez-Domínguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 2006;24:513-518 [PMID: 16886917]
29. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189-2204 [PMID: 19120703 DOI: 10.1111/j.1582-4934.2008.00533.x]
30. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013;52:297-303 [PMID: 22213236 DOI: 10.1002/mc.21864]
31. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, Christensen RN, Schmidt WN, McCaffrey AP. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010;90:1727-1736 [PMID: 20625373 DOI: 10.1038/labinvest.2010.126]
32. Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, Ninomiya M, Uchiyama H, Soejima Y, Maehara Y. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011;31:474-484 [PMID: 21199296 DOI: 10.1111/j.1478-3231.2010.02433.x]
33. Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and liver disease. Transl Res 2011;157:241-252 [PMID: 21420035 DOI: 10.1016/j.trsl.2011.01.008]
34. Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: fad or future of liver disease. World J Gastroenterol 2011;17:2536-2542 [PMID: 21633658 DOI: 10.3748/wjg.v17.i20.2536]
35. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-739 [PMID: 12007417]
36. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, Gandhi CR, Li S. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013;58:522-528 [PMID: 23178710 DOI: 10.1016/j.jhep. 2012.11.011]
37. Zeisel MB, Pfeffer S, Baumert TF. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol 2013;58:821-823 [PMID: 23085250 DOI: 10.1016/j.jhep. 2012.10.010]
38. Boutz DR, Collins PJ, Suresh U, Lu M, Ramírez CM, Fernández-Hernando C, Huang Y, Abreu Rde S, Le SY, Shapiro BA, Liu AM, Luk JM, Aldred SF, Trinklein ND, Marcotte EM, Penalva LO. Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem 2011;286:18066-18078 [PMID: 21402708 DOI: 10.1074/jbc. M110.196451]
39. Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D'Onorio De Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol 2012;56:855-861 [PMID: 22178270 DOI: 10.1016/j.jhep. 2011.11.017]
40. Mortimer SA, Doudna JA. Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure. Nucleic Acids Res 2013;41:4230-4240 [PMID: 23416544 DOI: 10.1093/nar/gkt075]
41. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D'Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotto E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S, Negrini M. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012;56:1025-1033 [PMID: 22473819 DOI: 10.1002/hep. 25747]
42. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:264-269 [PMID: 20018759 DOI: 10.1073/pnas. 0907904107]
43. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, Schmittgen TD, Croce C, Ghoshal K, Jacob ST. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50:1152-1161 [PMID: 19711427 DOI: 10.1002/hep. 23100]
44. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-5661 [PMID: 18521080 DOI: 10.1038/onc.2008.178]
45. Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, Cantz T, Sharma AD. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 2013;57:299-310 [PMID: 22821679 DOI: 10.1002/hep. 25984]
46. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, Kawada N. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012;61:1600-1609 [PMID: 22267590]
47. Fornari F, Milazzo M, Galassi M, Callegari E, Veronese A, Miyaaki H, Sabbioni S, Mantovani V, Marasco E, Chieco P, Negrini M, Bolondi L, Gramantieri L. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. Mol Cancer Res 2014;12:203-216 [PMID: 24324033 DOI: 10.1158/1541-7786. MCR-13-0312-T]
48. Ma D, Tao X, Gao F, Fan C, Wu D. miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 2012;4:483-488 [PMID: 23741247]
49. Estebaud E, Bieche I, Lapalus M, De Muynck S, Lada O, Martinot-Peignoux M, Duces A, Valla D, Bedossa P, Marcellin P, Vidaud M, Asselah T. Differential liver minRNAS expression in chronic hepatitis C patients at early stages of liver fibrosis. J Hepatol 2011;54:S315
50. Lendvai G, Jármay K, Karácsony G, Halász T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A. Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J Gastroenterol 2014;20:15343-15350 [PMID: 25386083 DOI: 10.3748/wjg.v20.i41.15343]
51. Wei J, Feng L, Li Z, Xu G, Fan X. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother 2013;67:387-392 [PMID: 23643356 DOI: 10.1016/j.biopha.2013.03.014]
52. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, Von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011;6:e26971 [PMID: 22066022 DOI: 10.1371/journal.pone.0026971]